cbdMD, Inc. (YCBD)

NYSEAMERICAN: YCBD · IEX Real-Time Price · USD
0.930
-0.080 (-7.92%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products.

The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, hempMD, and cbdMD Botanicals.

Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, drink mixes, and sleep, focus, and calming aids.

The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name; nootropic mushroom line under the ATRx brand; and hemp derived solutions under the hempMD brand.

It distributes its products through its e-commerce website, third-party e-commerce sites, select distributors and marketing partners, wholesalers, and various brick and mortar retailers in the United States.

The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019.

cbdMD, Inc. is headquartered in Charlotte, North Carolina.

cbdMD, Inc.
cbdMD logo
Country United States
Founded 2015
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 52
CEO T. Ronan Kennedy

Contact Details

Address:
8845 Red Oak Boulevard
Charlotte, North Carolina 28217
United States
Phone 704-445-3060
Website cbdmd.com

Stock Details

Ticker Symbol YCBD
Exchange NYSEAMERICAN
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001644903
CUSIP Number 12482W101
ISIN Number US12482W3097
Employer ID 47-3414576
SIC Code 2844

Key Executives

Name Position
T. Ronan Kennedy Interim Chief Executive Officer, Principal Executive Officer, Chief Financial Officer, Secretary and Treasurer
Dr. Sibyl Swift Ph.D. CSO, Vice President of Regulatory Affairs and Director
Zeb Booker Chief Technology Officer
John Weston Director of Investor Relations
Lance Blundell General Counsel
Robert Pettway Director of Public Relations
Francisco Mangual Senior Vice President of Sales
Shannon Charles Chief Marketing Officer
David Johnson Senior Vice President of Business Development

Latest SEC Filings

Date Type Title
Mar 27, 2024 424B4 Prospectus
Mar 26, 2024 EFFECT Notice of Effectiveness
Mar 19, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Mar 18, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 18, 2024 8-K Current Report
Mar 1, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 1, 2024 8-K Current Report
Feb 16, 2024 S-1 General form for registration of securities under the Securities Act of 1933
Feb 14, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Feb 14, 2024 DEF 14A Other definitive proxy statements